{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:10:30Z","timestamp":1786119030177,"version":"build-2736575974"},"reference-count":40,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2026,7,24]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effectiveness and safety of active pharmacotherapy for patent ductus arteriosus (PDA) initiated based on echocardiography-criteria versus expectant management in extremely preterm infants &lt;29\u2009w gestation in the first three weeks of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Systematic review with meta-analysis and trial sequential analysis (TSA). We searched PubMed, Embase, CENTRAL and Emcare for randomised trials published between 2010 and May 2026. We synthesised results using random-effects meta-analysis and conducted a TSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Extremely preterm infants with PDA considered as significant on echocardiography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Pharmacotherapy versus expectant management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Mortality by 36 weeks postconceptional age or before discharge and chronic lung disease (CLD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 12 trials involving 2344 extremely preterm infants. Meta-analysis found increased risk of mortality with active pharmacotherapy (RR 1.34, 95%\u2009CI 1.08 to 1.67; p=0.008, I\n                      <jats:sup>2<\/jats:sup>\n                      =0%; 12 randomised controlled trials (RCTs)). Number-needed-to-treat for an additional harmful outcome (i.e. mortality) was 25 (95% CI 17 to 100). On TSA conducted with the stringent alpha error 3.3% and beta 10%, the cumulative Z-score touched the O\u2019Brien\u2013Fleming monitoring boundary at the current sample size, supporting the meta-analysis findings under the specified TSA assumptions.\n                    <\/jats:p>\n                    <jats:p>\n                      For CLD, meta-analysis showed little or no difference (RR 0.99, 95%\u2009CI 0.92 to 1.06, p=0.74, I\n                      <jats:sup>2<\/jats:sup>\n                      =14%, 12 RCTs). The certainty of evidence was high for mortality and moderate for CLD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In extremely preterm infants, active pharmacotherapy for PDA based on current echocardiographic criteria in the first three weeks of life was associated with increased mortality with a clinically important number needed to harm. These findings should inform treatment decisions and discussions with parents while ongoing research seeks to identify infants who may benefit from treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420261303992.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/archdischild-2026-331024","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:20:34Z","timestamp":1786036834000},"page":"fetalneonatal-2026-331024","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Active pharmacotherapy versus expectant management of patent ductus arteriosus in extremely preterm infants: a meta-analysis with trial sequential analysis"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8481-5925","authenticated-orcid":false,"given":"Shripada C","family":"Rao","sequence":"first","affiliation":[{"name":"Perth Children\u2019s Hospital Neonatal Intensive Care Unit, Nedlands, Western Australia, Australia"},{"name":"The University of Western Australia School of Medicine, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Rath","sequence":"additional","affiliation":[{"name":"Neonatology, Canberra Hospital, Garran, Australian Capital Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Patole","sequence":"additional","affiliation":[{"name":"The University of Western Australia School of Medicine, Perth, Western Australia, Australia"},{"name":"Neonatology, King Edward Memorial Hospital for Women, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"2026080610202728000_archdischild-2026-331024v1.1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-303816"},{"key":"2026080610202728000_archdischild-2026-331024v1.2","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13071744","article-title":"Pulmonary Hemorrhage in Premature Infants: Pathophysiology, Risk Factors and Clinical Management","volume":"13","author":"Sahussarungsi","year":"2025","journal-title":"Biomedicines"},{"key":"2026080610202728000_archdischild-2026-331024v1.3","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/s41390-025-04067-0","article-title":"Association of patent ductus arteriosus duration with bronchopulmonary dysplasia and mortality: a cohort study","volume":"98","author":"Bonafiglia","year":"2025","journal-title":"Pediatr Res"},{"key":"2026080610202728000_archdischild-2026-331024v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41372-019-0511-8"},{"key":"2026080610202728000_archdischild-2026-331024v1.5","doi-asserted-by":"crossref","unstructured":"Ouyang Q , Bei F , Yan C , et al . Hemodynamically significant PDA impacts adverse outcomes in infants with BPD: a multicenter study. Pediatr Res 2026. doi:10.1038\/s41390-026-04772-4","DOI":"10.1038\/s41390-026-04772-4"},{"key":"2026080610202728000_archdischild-2026-331024v1.6","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s00431-024-05593-5","article-title":"Risk factors for acute kidney injury in very-low birth weight newborns: a systematic review with meta-analysis","volume":"183","author":"Hirano Arruda Moraes","year":"2024","journal-title":"Eur J Pediatr"},{"key":"2026080610202728000_archdischild-2026-331024v1.7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00467-019-4194-5","article-title":"Patent ductus arteriosus is associated with acute kidney injury in the preterm infant","volume":"34","author":"Majed","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2026080610202728000_archdischild-2026-331024v1.8","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00431-021-04153-5","article-title":"The evolution of cardiac point of care ultrasound for the neonatologist","volume":"180","author":"Singh","year":"2021","journal-title":"Eur J Pediatr"},{"key":"2026080610202728000_archdischild-2026-331024v1.9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpeds.2020.10.024","article-title":"A Pilot Randomized Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score (The PDA RCT)","volume":"229","author":"El-Khuffash","year":"2021","journal-title":"J Pediatr"},{"key":"2026080610202728000_archdischild-2026-331024v1.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305582"},{"key":"2026080610202728000_archdischild-2026-331024v1.11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jama.2025.23330","article-title":"Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial","volume":"335","author":"Laughon","year":"2026","journal-title":"JAMA"},{"key":"2026080610202728000_archdischild-2026-331024v1.12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpeds.2020.12.008","article-title":"Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial","volume":"233","author":"Roz\u00e9","year":"2021","journal-title":"J Pediatr"},{"key":"2026080610202728000_archdischild-2026-331024v1.13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/jamapediatrics.2025.1025","article-title":"Active Treatment vs Expectant Management of Patent Ductus Arteriosus in Preterm Infants: A Meta-Analysis","volume":"179","author":"Buvaneswarran","year":"2025","journal-title":"JAMA Pediatr"},{"key":"2026080610202728000_archdischild-2026-331024v1.14","article-title":"Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants","volume":"6","author":"Mitra","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080610202728000_archdischild-2026-331024v1.15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41390-025-03820-9","article-title":"Beneficial vs harmful effects of pharmacological treatment of patent ductus arteriosus: A Bayesian meta-analysis","volume":"98","author":"Villamor","year":"2025","journal-title":"Pediatr Res"},{"key":"2026080610202728000_archdischild-2026-331024v1.16","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn188"},{"key":"2026080610202728000_archdischild-2026-331024v1.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2026080610202728000_archdischild-2026-331024v1.18","doi-asserted-by":"crossref","unstructured":"Mitra S , Hebert A , Castaldo MP , et al . Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial (SMART-PDA). Arch Dis Child Fetal Neonatal Ed 2026. doi:10.1136\/archdischild-2026-330462","DOI":"10.1136\/archdischild-2026-330462"},{"key":"2026080610202728000_archdischild-2026-331024v1.19","doi-asserted-by":"crossref","DOI":"10.1007\/s00431-025-06130-8","article-title":"Heterogeneity in treatment response for patent ductus arteriosus: a meta-analysis","volume":"184","author":"Matsushita","year":"2025","journal-title":"Eur J Pediatr"},{"key":"2026080610202728000_archdischild-2026-331024v1.20","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026080610202728000_archdischild-2026-331024v1.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081903","article-title":"Core GRADE 1: overview of the Core GRADE approach","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"2026080610202728000_archdischild-2026-331024v1.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207418"},{"key":"2026080610202728000_archdischild-2026-331024v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.12.031"},{"key":"2026080610202728000_archdischild-2026-331024v1.24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamapediatrics.2020.1447","article-title":"Effect of Nonintervention vs Oral Ibuprofen in Patent Ductus Arteriosus in Preterm Infants: A Randomized Clinical Trial","volume":"174","author":"Sung","year":"2020","journal-title":"JAMA Pediatr"},{"key":"2026080610202728000_archdischild-2026-331024v1.25","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-304695"},{"key":"2026080610202728000_archdischild-2026-331024v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.08.062"},{"key":"2026080610202728000_archdischild-2026-331024v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.09.012"},{"key":"2026080610202728000_archdischild-2026-331024v1.28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000515415","article-title":"Early PARacetamol (EPAR) Trial: A Randomized Controlled Trial of Early Paracetamol to Promote Closure of the Ductus Arteriosus in Preterm Infants","volume":"118","author":"Schindler","year":"2021","journal-title":"Neonatology"},{"key":"2026080610202728000_archdischild-2026-331024v1.29","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41372-024-02022-1","article-title":"At a crossroads for early medical treatment of persistent patent ductus arteriosus in preterm infants","volume":"44","author":"Benitz","year":"2024","journal-title":"J Perinatol"},{"key":"2026080610202728000_archdischild-2026-331024v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.12.001"},{"key":"2026080610202728000_archdischild-2026-331024v1.31","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-024-04967-3","article-title":"Composite outcome measures in high-impact critical care randomised controlled trials: a systematic review","volume":"28","author":"Walker","year":"2024","journal-title":"Crit Care"},{"key":"2026080610202728000_archdischild-2026-331024v1.32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.17161\/kjm.vol19.24634","article-title":"Does Mortality Risk Increase with Active Treatment of Patent Ductus Arteriosus in Preterm Infants? A Critical Appraisal Skills Programme (CASP) Assessment of a Meta-Analysis","volume":"19","author":"Bohanon Franco","year":"2026","journal-title":"Kans J Med"},{"key":"2026080610202728000_archdischild-2026-331024v1.33","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-026-02244-3","article-title":"Active treatment vs. expectant management of patent ductus arteriosus in preterm infants: critical analysis of a meta-analysis","volume":"52","author":"Dani","year":"2026","journal-title":"Ital J Pediatr"},{"key":"2026080610202728000_archdischild-2026-331024v1.34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOP.0000000000001543","article-title":"Patent ductus arteriosus: emerging trial evidence firmly supports conservative management in preterm infants","volume":"38","author":"Parikh","year":"2026","journal-title":"Curr Opin Pediatr"},{"key":"2026080610202728000_archdischild-2026-331024v1.35","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14030576","article-title":"PDA in Prematurity: Rethinking a Decades-Old Debate in 2026","volume":"14","author":"Plessas-Azurduy","year":"2026","journal-title":"Biomedicines"},{"key":"2026080610202728000_archdischild-2026-331024v1.36","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2025-071425","article-title":"Patent Ductus Arteriosus in Preterm Infants","volume":"155","author":"Ambalavanan","year":"2025","journal-title":"Pediatrics"},{"key":"2026080610202728000_archdischild-2026-331024v1.37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpeds.2021.12.071","article-title":"International Variation in the Management of Patent Ductus Arteriosus and Its Association with Infant Outcomes: A Survey and Linked Cohort Study","volume":"244","author":"Isayama","year":"2022","journal-title":"J Pediatr"},{"key":"2026080610202728000_archdischild-2026-331024v1.38","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.17477","article-title":"Pharmacologic Therapies for Patent Ductus Arteriosus in Extremely Preterm Infants","volume":"9","author":"Mitra","year":"2026","journal-title":"JAMA Netw Open"},{"key":"2026080610202728000_archdischild-2026-331024v1.39","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41372-021-01277-2","article-title":"Natural evolution of the patent ductus arteriosus in the extremely premature newborn and respiratory outcomes","volume":"42","author":"de Carvalho Nunes","year":"2022","journal-title":"J Perinatol"},{"key":"2026080610202728000_archdischild-2026-331024v1.40","doi-asserted-by":"crossref","unstructured":"Battersby C , Levy PT , Gupta S , et al . Making sense of the evidence: designing randomised controlled trials for preterm infants with high-shunt volume patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2026. doi:10.1136\/archdischild-2025-330266","DOI":"10.1136\/archdischild-2025-330266"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2026-331024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:20:39Z","timestamp":1786036839000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/archdischild-2026-331024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":40,"alternative-id":["10.1136\/archdischild-2026-331024"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2026-331024","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}